The Importance Of CDMO Capacity For Viral Vectors: A Conversation With Forge's Dr. Timothy Miller

By Cytiva

There’s an increasing interest in treating rare and intractable diseases with personalized medicine, which has spurred high demand in gene therapy manufacturing. As more optimized production and research continues to develop new approaches to care, facilitated by science and technology, this demand is projected to multiply.

Since 2013, Dr. Timothy Miller, cofounder, President, and CEO of Forge Biologics, has watched the transformation of the cell and gene therapy space. He has seen the transition from the IPO classes of the latter half of the 2010s to the current market struggles amidst a global pandemic.

Forge Biologics began as a company targeting biologics for Infantile Krabbe Disease. Forge then relinquished the traditional development pipeline, instead establishing itself as a gene therapy development engine while pursuing its own scale-up work. The company is now positioned to address a growing need in a transformative space.

Dr. Miller sat down with The Business of Biotech podcast to discuss the importance of developing specialized CDMO capacity in an increasingly specialized development arena.